References
- Mason PJ, Morris VA, Balcezak TJ: Serotonin syndrome. Presen-tation of 2 cases and review of the literature. Medicine (Balti-more) 2000; 79:201–209
- Pan, JJ, Shen, WW: Serotonin syndrome induced by low-dose venlafaxine. Ann Pharmacother 2003; 37:209–211
- Birmes P. Coppin D, Schmitt L, Lauque D: Serotonin syndrome: A brief review. CMAJ 2003; 168:1439–1442
- Martin, TG: Serotonin syndrome. Ann Emerg Med 1996; 28: 520–526
- Sternbach H: The serotonin syndrome. Am J Psychiatry 1991; 148:705–713
- Mills KC: Serotonin syndrome: a clinical update. Crit Care Clin 1997; 13:763–783
- Nierenberg DW, Semprebon M: The central nervous system sero-tonin syndrome. Clin Pharmacol Ther 1993; 53:84–88
- McDaniel WW: Serotonin syndrome: Early management with cyproheptadine. Ann Pharmacother 2001; 35:870–873
- Gillman, PK: Serotonin syndrome treated with chlorpromazine. J Clin Psychopharmacol 1997; 17:128–129
- Gillman, PK: The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13:100–109
- Carbone JR: The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000; 18:317–325
- Friedman LS, Weinrauch LA, D'Elia JA: Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med 1987; 147:1495–1497
- Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185–202
- Shalev A, Hermesh H, Munitz, H: Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50:18–25
- Sakkas P, Davis JM, Janicak PG, Wang ZY: Drug treatment of neuroleptic malignant syndrome. Psychopharmacol Bull 1991; 27:381–384
- Kline SS, Mauro LS, Scala-Barnett DM, Zick D: Serotonin syn-drome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 1989; 8:510–514
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
- Bohan TP, Helton E, McDonald I, Konig S, Gazitt S, Sugimoto T, Scheffner D, Cusmano L, Li S, Koch G: Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001; 56:1405–1409
- Hermesh H, Manor I, Shiloh R, Aizenberg D, Benjamini Y, Munitz H, Weizman A: High serum creatinine kinase level: Possi-ble risk factor for neuroleptic malignant syndrome. J Clin Psy-chopharmacol 2002; 22:252–256
- Boyer EW, Shannon M: The serotonin syndrome. NEJM 2005; 352:1112–1120